Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Analysts at Oppenheimer issued their FY2018 EPS estimates for Eiger Biopharmaceuticals in a research note issued on Monday. Oppenheimer analyst J. Olson expects that the biotechnology company will post earnings of ($3.88) per share for the year. Oppenheimer has a “Buy” rating and a $26.00 price target on the stock. Oppenheimer also issued estimates for Eiger Biopharmaceuticals’ FY2019 earnings at ($4.01) EPS and FY2020 earnings at ($4.44) EPS.
A number of other analysts also recently issued reports on EIGR. ValuEngine raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Ladenburg Thalmann Financial Services assumed coverage on Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They set a “buy” rating and a $32.00 price objective for the company. Zacks Investment Research upgraded Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Tuesday, January 9th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $17.00 price objective (down previously from $35.00) on shares of Eiger Biopharmaceuticals in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $27.25.
Eiger Biopharmaceuticals (EIGR) traded down $0.25 during trading hours on Thursday, hitting $9.20. The company had a trading volume of 14,105 shares, compared to its average volume of 166,808. The company has a current ratio of 5.85, a quick ratio of 5.78 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $100.00, a P/E ratio of -1.94 and a beta of 1.70. Eiger Biopharmaceuticals has a twelve month low of $6.10 and a twelve month high of $16.20.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last released its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.09).
Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its position in shares of Eiger Biopharmaceuticals by 295.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 8,748 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in Eiger Biopharmaceuticals in the 3rd quarter worth $147,000. Renaissance Technologies LLC raised its position in Eiger Biopharmaceuticals by 22.8% in the 4th quarter. Renaissance Technologies LLC now owns 97,013 shares of the biotechnology company’s stock worth $1,353,000 after purchasing an additional 18,000 shares during the period. P.A.W. Capital Corp raised its position in Eiger Biopharmaceuticals by 25.0% in the 4th quarter. P.A.W. Capital Corp now owns 100,000 shares of the biotechnology company’s stock worth $1,395,000 after purchasing an additional 20,000 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new position in Eiger Biopharmaceuticals in the 2nd quarter worth $272,000. Institutional investors and hedge funds own 69.03% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/03/16/brokers-set-expectations-for-eiger-biopharmaceuticals-incs-fy2018-earnings-eigr.html.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.